£66.8M
The Series C financing was led by Advent Life Sciences with backing from several new and existing institutional investors to accelerate product development and scale operations.
"We are delighted to partner with Proximie and a world class group of investors as the company expands its global footprint and product capabilities. The company is a perfect fit for our ethos of backing best-in-class innovative life sciences businesses that have the capability to positively impact human health and healthcare delivery in paradigm changing ways."
Advent Life Sciences + 10 others
.png)